BioSpaceOriginal article
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
Phase 2positivePositive
AI Analysis
Summary
Silence Therapeutics achieved positive mid-stage results with its siRNA drug in polycythemia vera, validating the therapeutic approach but setting a high bar for competing programs from Takeda, Agios, and Disc Medicine.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Mid-stage win in polycythemia vera validates siRNA therapeutic approach
Importance:7/10
Sentiment:
0.75
rare diseaseblood cancersiRNApolycythemia veraclinical datacompetitive landscape
Related Companies
Read the original article
Published by BioSpace on August 11, 2026 11:01 AM